Literature DB >> 3242582

The disposition of ketoprofen enantiomers in man.

B C Sallustio1, Y J Purdie, A G Whitehead, M J Ahern, P J Meffin.   

Abstract

1. The disposition of ketoprofen enantiomers was studied in 21 patients taking racemic ketoprofen (Orudis SR). 2. In each patient the plasma concentrations of the R- and S-enantiomers were similar at all times over a 24 h dosing interval. The mean (+/- s.e. mean) time-averaged plasma ketoprofen concentrations over the dosage interval were 0.76 (+/- 0.06) mg l-1 for R-ketoprofen and 0.78 (+/- 0.06) mg l-1 for S-ketoprofen. 3. Creatinine clearances for the 21 patients ranged from 6-162 ml min-1. There was no correlation between creatinine clearance and time-averaged plasma concentration for either R- or S-ketoprofen. 4. Approximately 30% of the dose was recovered in urine (unconjugated + glucuronide conjugate) and this was made up of 43% R-ketoprofen and 57% S-ketoprofen. Because of incomplete urine recoveries of ketoprofen it was not possible to determine whether inversion from the R- to the S-enantiomer takes place in man. 5. The data suggest that in terms of total (bound + unbound) ketoprofen, half the concentration value derived by a non-enantiospecific analysis would give a reasonable approximation of the pharmacologically active S-enantiomer concentration in plasma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3242582      PMCID: PMC1386593          DOI: 10.1111/j.1365-2125.1988.tb05317.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  [Biological behavior: serum levels, excretion and biotransformation of (3-benzoylphenyl)-2-propionic acid, or ketoprofen, in animals and men].

Authors:  P Populaire; B Terlain; S Pascal; B Decouvelaere; A Renard; J P Thomas
Journal:  Ann Pharm Fr       Date:  1973-12

2.  The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs.

Authors:  A J Hutt; J Caldwell
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

3.  Pharmacokinetics of ketoprofen in the elderly.

Authors:  C Advenier; A Roux; C Gobert; P Massias; O Varoquaux; B Flouvat
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Pharmacokinetic profile of controlled release ketoprofen in elderly patients.

Authors:  M J Dennis; P C French; P Crome; M Babiker; J Shillingford; R Hopkins
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

5.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  Ketoprofen-aspirin interactions.

Authors:  R L Williams; R A Upton; J N Buskin; R M Jones
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses.

Authors:  R T Foster; F Jamali; A S Russell; S R Alballa
Journal:  J Pharm Sci       Date:  1988-03       Impact factor: 3.534

8.  Pharmacokinetics of ketoprofen in patients with chronic renal failure.

Authors:  G Stafanger; H W Larsen; H Hansen
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

9.  Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.

Authors:  P J Meffin; D M Zilm; J R Veenendaal
Journal:  J Pharmacol Exp Ther       Date:  1983-12       Impact factor: 4.030

10.  Enantiospecific high-performance liquid chromatographic analysis of 2-phenylpropionic acid, ketoprofen and fenoprofen.

Authors:  B C Sallustio; A Abas; P J Hayball; Y J Purdie; P J Meffin
Journal:  J Chromatogr       Date:  1986-01-24
View more
  7 in total

Review 1.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.

Authors:  F Lapicque; N Muller; E Payan; N Dubois; P Netter
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of ketoprofen and its enantiomers.

Authors:  F Jamali; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.

Authors:  P J Hayball; R L Nation; F Bochner; L N Sansom; M J Ahern; M D Smith
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

6.  Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate.

Authors:  G Geisslinger; S Menzel; K Wissel; K Brune
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

7.  Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis.

Authors:  Franciszek Główka; Marta Karaźniewicz-Łada; Edmund Grześkowiak; Dominika Rogozinska; Wojciech Romanowski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-24       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.